Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 | Synapse
September 10, 2025Open Access
Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Puntos clave
The association of mhc-i or mhc-ii with pfs and orr was examined in patients.
Results indicate the potential significance of mhc-i or mhc-ii levels in predicting response rates.
Utilizing an observational analysis approach, data were collected from patients treated with nivo and relatlimab.
These findings support the need for further exploration of mhc biomarkers in advanced melanoma treatment.
Resumen
Association between MHC-I or MHC-II and PFS or ORR in patients treated with NIVO + RELA or NIVO.